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1.  Introduction
‘There is no health without mental health’.[1,2] 
Mental disorders are highly prevalent among 
people living with HIV/AIDS (PLWHA), with 
major depressive disorder (MDD) occurring 
almost twice as frequently among this group than in the general 
population.[3] Mental disorders may increase an individual’s risk 
for HIV infection through increased social vulnerability, altered 
risk behaviour, associated substance misuse and loss of control 
within sexual relationships. Conversely, such disorders may also 
arise as a direct result of HIV neuro-invasion or psychosocial 
stressors, or due to complications of antiretroviral therapy 
(ART). [4,5] 
Despite their prevalence, mental disorders are often under-
diagnosed or inadequately managed in PLWHA. The impact of 
untreated mental disorders on health outcomes is substantial. It 
is imperative that clinicians caring for HIV-positive individuals 
actively screen for, diagnose and manage mental disorders in 
this population.[6]
2. Overview of the guideline
This guideline is intended to improve primary care HIV 
clinicians’ knowledge and capacity to manage mental health 
disorders. It is also intended to heighten HIV clinicians’ 
awareness of the need to integrate HIV and mental healthcare 
within their daily practice.[7]
The following conditions and issues are addressed here:
• HIV testing in the context of mental disorders
• common mental disorders (CMDs)
• severe mental disorders (SMDs)
• HIV-associated neurocognitive disorders (HANDs)
• grief
• healthcare worker (HCW) burnout and vicarious trauma.
These guidelines do not encompass substance use disorders or 
triple diagnosis (HIV/mental disorder/substance use disorder), 
or mental disorders among children and adolescents; these 
topics will be covered in separate, future guidelines.
3.  Principles of HIV testing 
in patients with mental 
disorders 
• All patients with mental disorders (in-/out-patients, volun-
tary/involuntary patients admitted under the Mental Health 
Care Act) should be offered HIV testing, HIV-prevention/
risk-reduction education and access to condoms
• The presence of a mental disorder does not automatically 
equal incapacity to consent to HIV testing
• Capacity to consent to HIV testing must therefore be assessed 
on an individual basis, particularly in patients with SMDs
• For capacity to consent, patients should be able to:
• understand why they are being tested
• understand and report on the consequences of a negative 
or positive test result
• report how they are likely to respond to either result
• Patients should be included in decision-making about their 
HIV testing, as far as possible in all cases
• If the patient is assessed as being incapable of giving informed 
voluntary consent (e.g. active psychosis, dementia), then 
proxy consent may be sought
• Proxy consent 
• Consent is given by someone else acting in the best interests 
of the patient, e.g. a senior clinician in charge of the case
• The reasons for testing and the process must be docu-
mented carefully
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• There may be a need to disclose the 
results to the carer, if the patient has 
irreversible neurocognitive impairment, 
with cognisance of potential stigma/
discrimination
• Disclosure
• All medical information should be 
kept confidential at all times
• Information should preferably be 
released only with patient con sent, 
unless the information is relevant to 
clinical management/medical aid pro-
cedures
• The procedure to follow when testing for 
HIV in patients with mental disorders is 
shown in Fig. 1.[8,9]
4.  Assessment and 
diagnosis of CMDs
The term ‘common mental disorder’, used to 
describe disorders that are highly prevalent in 
the general population (usually occurring at 
rates >10%), typically includes:
• depressive disorders
• anxiety disorders
• substance use disorders (not included in 
this guideline).[10]
Box 1 provides an overview of CMD pre-
valence. In South Africa (SA), 26 - 38% of 
PLWHA have a CMD (v. 12.6% of the general 
population).[6] CMDs have not decreased in 
prevalence with the introduction of ART.
4.1 Screening
Clinicians should screen routinely for CMDs, 
because patients rarely volunteer information 
about their mental state. Box 2 includes three 
questions to ask patients. Due to the high 
prevalence of gender-based violence (GBV) in 
SA, we recommend clinicians also incorporate 
screening for GBV.[11]
Certain patients may require more intensive 
screening, including: 
• those at their first ART assessment
• those responding poorly to ART (detectable 
viral load (VL)/adherence issues)
• those exhibiting worrying behaviour (look-
ing anxious/depressed, expressing sui cidal 
ideation or self-harm).
 
Patients who respond positively to one of 
the brief screening questions should be 
administered a validated screening tool that 
is appropriate for primary healthcare settings, 
such as the Patient Health Questionnaire 
(PHQ)-9 (Fig. 2).[12]
4.2 Risk assessment
It is important to assess suicide risk. Clinicians 
should always ask about suicidal ideation in 
patients with depressive symptoms. High risk 
is indicated by: 
• a clear plan for ending life
• an identified lethal method
• a previous suicide attempt
• a lack of social support
• severe (psychotic) depressive disorder. 
See also the ‘SAD PERSONS’ scale (Fig. 3).[13]
4.3 Mental state assessment 
Assessing the patient’s mental state is as 
important as a physical examination. Clini-
cians should conduct and document a ‘mental 
state examination’ (Box 3) at each visit. 
Box 1. Overview of CMD 
prevalence
• Two-fold increase in prevalence in HIV-
positive individuals[3,8] 
• In SA, 26 - 38% of PLWHA have a CMD 
(v. 12.6% of the general population)[9] 
• Some 20 - 60% of PLWHA are affected 
by some form of psychiatric disorder[10] 
(depressive disorders are most common)
• CMDs are not decreasing in the ART era
• CMD prevalence is influenced by 
viral central nervous system (CNS) 
pathology, concomitant psychosocial 
stressors and the nature of HIV as a life-
threatening and stigmatised illness
• CMDs often go undiagnosed and 
untreated in this population
Box 2. Screening for depression 
and GBV
Brief routine screening questions for 
depression
• How have you been in the past month/
since your last visit?
• Have you been feeling more stressed 
than usual?
• Have you been feeling down, low, heart-
sore or depressed?
Brief screening questions for GBV
• How are things going in your 
relationship with your partner?
• Have you ever been emotionally, 
sexually or physically victimised?
Testing for HIV in patients with mental disorders
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4.4  Depression in PLWHA 
(including MDD and less 
severe types)
Up to 25% of PLWHA in SA are thought to 
suffer from some form of depression during 
the course of the illness. Severe depression, 
also known as MDD, occurs in about 5 - 10% 
of patients, while minor depressive disorders 
are diagnosed in about 15 - 20%.[6,10] Even 
mild depression can lead to erratic adherence, 
poor care engagement and ultimately to 
more serious outcomes. Major depression 
is diagnosed by the presence of five or more 
of the symptoms listed in section 4.4.1 for at 
least two weeks, while minor depression is 
diagnosed when fewer symptoms are present 
and/or for shorter periods. 
4.4.1  Symptoms of depressive 
disorders
Depressive disorder is characterised by five or 
more of the following occurring together in a 
two-week period:
• EITHER: depressed mood almost all day 
every day 
• OR: loss of interest or enjoyment of usually 
pleasurable activities for most of the day
• AND (occurring nearly every day): 
• significant weight loss when not dieting 
or due to medical illness, or weight 
gain (e.g. >5% body weight change in a 
month), or decreased/increased appetite
• insomnia or hypersomnia
• psychomotor agitation or retardation 
(observ able by others, not merely sub-
ject ive feelings of restlessness or of being 
slowed down)
• fatigue or loss of energy
• feelings of worthlessness or excessive 
or inappropriate guilt (which may be 
delusional) – not merely self-reproach or 
guilt about being sick
• diminished ability to think or concen-
trate, or indecisiveness (either by sub-
jective account or as observed by others)
• recurrent thoughts of death (not just 
fear of dying), recurrent suicidal idea tion 
Box 3. Recording the mental 
state examination
Document the mental state examination, as 
for physical examination:
• appearance and behaviour: grooming, eye 
contact, motor activity, etc.
• level of consciousness: orientation for 
time, person, place
• cognitive function (see section 6: 
HANDs)
• mood: objectively euthymic, depressed, 
elevated
• speech, form and content of thinking: 
flow of speech, coherence and content 
of thinking (delusions, pre-occupations, 
ruminations)
• perceptual abnormalities: evidence of 
hallucinations
• insight into own condition
Over the past 2 weeks how often have you been 





1. Little interest or pleasure in doing things
2. Feeling down, depressed or hopeless
3. Trouble falling or staying asleep; or sleeping too 
    much
4. Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself or that you are a 
    failure or have let yourself or your family down
7. Trouble concentrating on things such as reading 
    the newspaper or watching TV
8. Moving or speaking so slowly that others could 
    and restless that you have been moving around 

































Over the past 2 weeks how often have you been 





    hurting yourself in some way
Add columns
Total
0 - 4: No depression
5 - 9: Mild depression
10 - 14: Moderate depression 
15 - 19: Moderately severe
20 - 27: Severe
have these problems made it for you to do work, 























Fig. 2. Patient Health Questionnaire (PHQ)-9.











3 - 4 points
0 - 2 points
5 - 6 points
7 - 10 points
Sex: male gender represents a higher risk
Age: extremes of age are at higher risk (e.g. <18 years and >55 years)
Depression or other psychiatric comorbidity are at higher risk
Previous attempts: those with a past history of [suicide] attempts are at higher risk
No spouse
Organised plan
Ethanol/alcohol or other substance use/abuse
Rational thinking loss, e.g. psychosis with command hallucinations
Social support: no social support confers a higher risk
Sickness: medical or psychiatric illness may confer a higher risk
Close follow-up needs to be ensured and hospitalisation considered
Hospitalisation is strongly considered
Ensure hospitalisation and consider involuntary admission if necessary
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without a specific plan, or a suicide attempt or a specific plan for 
committing suicide.[14] 
Psychotic symptoms may occur in severe depressive disorders. These 
usually consist of delusions (guilt, nihilistic, of death, occasionally 
paranoid) and occasionally hallucinations (these are usually transient).
If the screen is positive for a CMD, conduct and document a mental 
state examination (see Box 3).
4.4.2  Differential diagnosis of depression
• Minor or sub-threshold depressive dis orders are characterised by the 
presence of some symptoms, but do meet all criteria for MDD
• Major depression
• Adjustment disorder: a depressive reaction to psychosocial stressors 
including HIV diagnosis
• Bereavement (see section 7)
• Mood disorder secondary to a medical condition/substance, e.g. 
HIV, hypothyroidism, efavirenz (EFV), alcohol
• Bipolar disorder: there is usually history of a previous episode of 
elevated mood resulting in abnormal behaviour, e.g. reduced sleep, 
increased energy/libido/risk-taking, etc.
4.4.3  Management of MDD (moderate to severe 
depression according to the PHQ-9)
4.4.3.1 Hospitalisation
The patient requires hospitalisation:
• if there is a high suicide risk
• in complex cases: the presence of psychosis and/or minimal social 
support and/or a poor response to out-patient treatment and/or a 
diagnostic dilemma
• in complex medical comorbidity (to monitor antidepressant medi-
cation)
• in the event of severe psychomotor retardation or no eating/drinking.
4.4.3.2 Initiation of antidepressant treatment
The initiation of antidepressant therapy in patients with CMDs is based 
on a step-wise approach, using the PHQ-9 as a guide to diagnosis, 
management and follow-up (Box 4). It is essential to remember that one 
‘starts low and goes slow’ as patients with HIV/AIDS are often more 
sensitive to side-effects of medication.
4.4.5 Psychotherapy[15]
• If available, patients should be referred for psychological assessment 
and treatment
• Evidence-based psychotherapy interventions for PLWHA and 
de press ion include:
• cognitive-behavioural therapy (CBT): a form of psychotherapy 
addressing dysfunctional emotions and maladaptive ideas through 
a goal-directed systematic process
• interpersonal therapy (IPT): a form of psychotherapy that is time-
limited and encourages patients to regain control of mood and 
functioning through the therapeutic alliance 
• group IPT (IPT-G): a form of therapy that employs the same 
basic structure and focus of individual IPT, though modified to 
capitalise on the group format
• Key determinants of successful therapy include the motivation of 
patients to attend multiple sessions and the access to clinics/times. 
4.5 Anxiety disorders 
Anxiety disorders in PLWHA are common. Some studies report that 
between 20% and 60% of HIV-positive adults suffer from some form 
of psychiatric disorder. The most recent general population study of the 
prevalence of mental disorders in SA was the SASH study, which reported 
a combined 12-month prevalence of depressive and anxiety disorders of 
12.6%. [6] It is important to recognise and treat anxiety disorders as they 
have been associated with increased rates of poor treatment compliance 
and high-risk behaviour. Quality of life is also adversely affected by 
anxiety disorders (Table 1).
5. SMDs and HIV/AIDS
These disorders occur less frequently in the general population (usually 
at rates <5%) and include:
• schizophrenia
• bipolar mood disorder
• MDD with psychotic features.
Box 5 describes the prevalence and impact of SMDs.
5.1 Diagnosis of SMDs
SMDs in PLWHA can often be classified as ‘primary’ or ‘secondary’. 
Primary SMDs often occur prior to HIV infection while secondary 
Box 4. Introducing an antidepressant: ‘Start low and 
go slow’*
• Initiate 20 mg fluoxetine (or similar) at the lowest available dose 
and refer to psychosocial support services where available
• Reassess using the PHQ-9 at 2 - 4 weeks and for side-effects (e.g. 
irritability, nausea, headache, disturbed sleep patterns); most 
side-effects settle within 2 weeks
• If after a total of 6 - 8 weeks there is no/minimal improvement, 
then increase the dose and reassess with the PHQ-9 in 4 - 6 weeks
• If after reassessment there is still no improvement, then up-refer
*  Fluoxetine and amitriptyline are the only antidepressants on the primary-level essential drugs list. Nurses 
are not currently permitted to prescribe – refer to a doctor. If unsure at any point, then phone the referral 
centre for advice. If the depression worsens at any point, or if suicide risk increases, then refer the patient. 
Box 5. Prevalence and impact of SMDs
Prevalence
• HIV among those with SMDs: 2.6 - 59.3% in sub-Saharan Africa[8]
• SMDs in the HIV-positive population: up to 15% 
• New-onset psychosis among the HIV-positive population: 
0.2 - 15.2%[16]
Impact
• SMDs lead to an increased risk of acquiring and transmitting 
HIV
• SMDs may impact adherence to psychiatric treatment and ART
• HIV disease progression can be associated with secondary 
psychiatric disorders, which often improve with ART
• Integrated care of both conditions improves outcomes[7] 
• Successful ART is more likely if there is: 
• no substance abuse
• no history of homelessness/incarceration 
• retention in psychiatric care
• adherence to psychiatric treatment[16] 
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SMDs arise as a consequence of HIV infection. Both are responsive to a 
combination of psychotropic medication and ART. 
A careful approach will help to differentiate primary SMDs (with 
comorbid HIV) (Fig. 4a) from secondary SMDs resulting directly from 
HIV or an opportunistic infection (Fig. 4b). 
Clinicians must:
• conduct a thorough history: presenting symptoms, temporal relation-
ship to HIV diagnosis, family/past psychiatric history
• conduct a comprehensive physical and neurological examination: 
this is essential to exclude underlying medical causes for psychiatric 
symptoms, e.g. opportunistic infections (particularly CNS pathology 
– toxoplasmosis/tuberculosis or cryptococcal meningitis), delirium or 
medication side-effects
• perform the following investigations: vital signs, urine dipstix, blood 
glucose, full blood count (FBC), creatinine and estimated glomerular 
filtration rate (eGFR), CD4+ count, lumbar puncture; may also 
perform alanine transaminase (ALT)/liver function tests (LFTs), 
syphilis serology, thyroid stimulating hormone (TSH), VL testing 
and a computed tomography (CT) scan, if these are indicated on the 
basis of history and examination findings.
5.2 Management of SMDs 
• Requires a multidisciplinary team approach, and where possible, 
integrated care including the involvement of community members 
and allied professionals
• Adherence support via treatment supporter/support groups and 
careful monitoring are key; patients should be educated/counselled 
regarding mental disorders and HIV to improve insight
• Poly-pharmacy (antidepressants, anticonvulsants, antipsychotics and 
ART): try as far as possible to rationalise to once daily dosing; 
patients on complex regimens should be reviewed regularly with a 
view to simplification
• Patients are more vulnerable to medication side-effects (e.g. extra-
pyramidal side-effects while receiving antipsychotics) and should be 
monitored closely.
• See Table 2. 
5.3 Starting ART in SMD: Use of EFV
Clinicians should follow standard national guidelines when initiating 
patients with SMDs on ART. EFV can often be used safely in patients 
with CMDs and in most with SMDs.[17] Routinely avoiding EFV for fear 
Table 1. Common anxiety disorders
Anxiety 
disorder* Features Medication options Psychotherapy
GAD • Pervasive physical and psychological symptoms of anxiety interfere 
with normal functioning (work, studying, activities of daily living, 
socialising) and/or cause significant distress
Medication options for all 
anxiety disorders include:
• SSRI antidepressant at doses 
as for MDD
• short-term (2 weeks) 
benzodiazepines, e.g. 1 - 2 mg 
lorazepam nocte/prn, 
10 - 30 mg oxazepam daily
• CBT
PD • Recurrent panic attacks (acute severe anxiety/panic: palpitations, 
sweating, tremor, feelings of choking, inability to breathe, feelings of 
impending doom, fear of death from symptoms)
• First panic attack often unexpected and unrelated to external stimulus
• Subsequent attacks may become associated with particular situations, 
leading to avoidance, e.g. fear of crowded places (agoraphobia)
• Isolated panic attacks can occur as part of GAD and depressive 
disorders
• Frequently associated with substance use disorders
• As above • CBT
PTSD • Onset after experiencing or witnessing a serious traumatic event 
(rape, assault, accidents)
• Symptoms may occur soon after the event or with delayed onset: 
intrusive memories (reliving, flashbacks, nightmares), hyper-arousal 
(increased startle response, anxiety symptoms) and avoidance 
(avoiding situations which remind the person of the traumatic event, 
numbing, and feelings of a foreshortened future)
• As above • Trauma counselling
• CBT
• Note: those recently 
exposed to trauma 




these may increase 
the risk of PTSD
OCD • Irrational thoughts or fears which are intrusive (obsessions), 
commonly fears of contamination or of not having completed an 
activity correctly, which results in compulsive rituals, e.g. repeated 
hand-washing, checking of activities
• As above • CBT
SSRI = selective serotonin reuptake inhibitor; MDD = major depressive disorder; CBT = cognitive-behavioural therapy; GAD = generalised anxiety disorder; PD = panic disorder;  
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Table 2. Commonly used drugs and their interactions[19,20]*
Class and drug Dosage Possible side-effects Possible drug interactions
SSRIs 
Fluoxetine 20 - 60 daily Headache, nausea, vomiting, irritability 
(initially), sexual dysfunction
EFV: potential increase in EFV levels
Monitor for worsening of neuropsychiatric conditions
Citalopram/
Escitalopram
10 - 20/5 - 10 mg 
daily
Headache, nausea, vomiting, irritability 
(initially), sexual dysfunction
Generally nil clinically significant drug interactions
PIs: potential for decrease citalopram dose
Sertraline 50 - 100 mg daily Headache, nausea, vomiting, irritability 
(initially), sexual dysfunction
Generally nil clinically significant drug interactions; 
however, EFV may decrease dose of sertraline so titrate to 
effect
TCAs
Amitryptaline 25 - 100 mg nocte Sedation, anticholinergic side-effects – 
urinary retention, worsening confusion 
in older patients, constipation
Fatal in overdose
Amitryptaline and PIs may increase the concentration of 
amitryptaline; potential cardiac arrhythmia abnormalities 
due to increased dose of amitryptaline
SNRIs 
Venlafaxine 75 - 225 mg daily Potential for withdrawal syndrome if 
stopped quickly
Initial irritability and GI side-effects 
Sexual side-effects
Generally well tolerated
EFV and NVP may decrease venlafaxine concentration
PIs may increase venlafaxine concentration
Tetracyclic 
antidepressants
Mirtazepine 30 - 60 mg nocte Sedation, weight gain NVP and EFV potentially increase mirtazepine clearance
Trazodone 50 - 150 mg nocte Sedation NB: PI/r may increase trazodone dramatically – monitor 
carefully
NDRIs
Bupropion XL 150 - 300 mg 
daily
Irritability, anxiety, tremulousness, 
paraesthesias, insomnia, seizures
EFV and PIs: potential for decreasing the dose of bupropion
Antipsychotics
FGAs
Haloperidol 0.5 - 5 mg nocte EPSEs (dystonia, tremor, akathisia, 
cogwheeling, bradykinesia), NMS
PI/r may increase haloperidol concentration
EFV may decrease haloperidol concentration
Chlorpromazine 25 - 200 mg in 
divided doses
Sedation, anticholinergic side-effects, 
NMS
PI/r may increase chlorpromazine concentrations
SGAs
Risperidone 0.5 - 4 mg nocte EPSE, sedation Risperidone levels may increase with PIs
Monitor for EPSEs and NMS
EFV and NVP may decrease risperidone concentrations
Quetiapine 25 - 600 mg Sedation, cardiac issues (QT 
prolongation – rare)
PI/r: potentially increased levels of quetiapine with increased 
sedation
EFV and NVP may decrease levels of quetiapine
Olanzapine 5 - 20 mg Sedation, metabolic syndrome – 
recommend lipogram if available
Probable interactions with PIs
PIs: decreased concentration of olanzapine, may need to 
increase dose or choose alternative agent
Aripiprazole 5 - 30 mg Akathisia, sedation PI/r could potentially increase aripiprazole concentrations
EFV and NVP could decrease aripiprazole concentrations
Clozapine 25 - 250 mg Neutropaenia
Best to avoid without specialist support
Probable interactions with PIs
Possible increased concentration with PIs and possible 
increased risk of sedation and seizures
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of worsening psychosis/depression is not warranted, especially since 
EFV has a more favourable side-effect profile, lower pill burden and 
fewer drug-drug interactions with psychiatric medications than other 
available alternatives (nevirapine and lopinavir/ritonavir). 
Milder neuropsychiatric side-effects of EFV (vivid dreams, dizziness), 
which typically resolve within 2 - 4 weeks, can be managed with 
re assurance.[18] Should a patient develop new-onset or worsening of pre-
existing psychosis with a temporal relationship to EFV introduction, and 
the psychosis persists despite psycho-pharmacological management, 
then the clinician should consider switching from EFV to an alternative 
agent. If a patient cannot tolerate EFV side-effects, then it may be 
necessary to switch to an alternative ARV. 
The use/initiation of EFV in patients who are currently psychotic 
or severely depressed remains controversial. If available, consider 
alternative regimens as there currently is no published literature on 
the outcomes of EFV in psychotic/depressed individuals. If alternatives 
are unavailable, contraindicated or involve significant drug-drug 
interactions, then initiate EFV and monitor carefully.
5.4  Diagnosis and management of 
secondary SMDs 
It is helpful to establish whether the SMD (psychosis or manic epi-
sode) is due to an underlying primary mental disorder or is secondary 
to HIV infection. Primary disorders require the initiation of psycho-
tropic treatment and an assessment of whether HIV disease is currently 
contributing to the disorder. If patients do not meet National Department 
of Health (NDoH) criteria for ART initiation and are not considered 
to have HIV-associated SMD, then they can be referred to out-patient 
HIV services when discharged. Where the SMD is either thought to be 
secondary to HIV or where a primary SMD is being aggravated by HIV, 
ART and psychotropic treatment should be given in hospital. 
5.5  SMDs secondary to HIV infection 
• SMDs secondary to HIV infection are often associated with:
• cognitive impairment (memory deficits and psychomotor slowing)
• significant immune-compromise: stage III/IV WHO disease, 
CD4+ counts <350 cell/µl and/or high VLs
• some atypical mental state features, e.g. irritability, non-auditory 
hallucinations (i.e. visual or other), and a lack of personal or family 
history of mental disorders (i.e. no or little genetic loading)
• no/poor response to psychotropic treatment.
• Management includes:
• commencing ART in line with the NDoH guidelines
• using low-dose anti-psychotics (haloperidol, risperidone, quetia-
pine) for psychosis
• patients with mania due to HIV may respond well to second-
generation antipsychotics (SGAs) (risperidone, quetiapine, 
olanzapine, aripiprazole)
• considering mood stabilisers in persistently manic patients 
(consult with a psychiatrist).
6.  HIV-associated 
neurocognitive disorders
HIV-associated neuropathological disease presents with a characteristic 
sub-cortical deficit pattern including: psychomotor slowing, impaired 
memory, attention, language, executive functioning and behavioural 
apathy. In patients receiving ART, a mixed cortical-subcortical picture 
is observed (less psychomotor slowing, more executive function, 
language and visuo-spatial difficulties). Classification into various 
HAND categories (Box 6) is determined by the extent of neurological 
and functional impairment:
• mild neurocognitive disorder (MND)
• HIV-dementia (HIV-D).[21]
Table 2 (continued). Commonly used drugs and their interactions[19,20]*
Class and drug Dosage Possible side-effects Possible drug interactions
Mood stabilisers
Lithium 400 - 800 mg Lithium toxicity that may be life-
threatening
Monitor levels regularly once steady 
state is reached
Relative contraindication to avoid with TDF
Potential risk for increased acute kidney injury
Sodium 
valproate
200 - 800 mg Sedation, thrombocytopenia, toxic 
valproate levels if not monitored 
regularly
Interaction with AZT (increased AZT levels)
PI/r may decrease valproate and increase PI
Monitor levels closely
Lamotrigine 25 - 200 mg SJS Possible interactions with PIs; decreased dose of 
lamotrigine
May need to increase/titrate doses of lamotrigine
Carbamazepine 100 - 200 mg bd Sedation, syndrome of inappropriate 
ADH, skin rash, cognitive dulling, 
decreased white cell count
NVP and EFV: decreased carbamazepine, decreased EFV
PI/r: increased carbamazepine, decreased PI
Benzodiazepines
Alprazolam 1 - 2 mg daily Sedation, dependence PIs increase concentration of alprazolam
Diazepam 10 - 30 mg/day Sedation, respiratory depression and 
ataxia
PIs increase diazepam
SSRIs = selective serotonin reuptake inhibitors; TCAs  = tricyclic antidepressants; SNRIs = serotonin noradrenaline reuptake inhibitors; GI = gastrointestinal; NDRIs = noradrenaline dopamine reuptake 
inhibitors; FGAs = first-generation antipsychotics; SGAs = second-generation antipsychotics; EPSEs = extra pyramidal side-effects; NMS = neuroleptic malignant syndrome; ADH = antidiuretic 
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6.1 Screening
• Without screening (excluding HAND 
suffer ers presenting to hospital with con-
fusional states/psychosis), many patients 
with gradual neurodegenerative changes 
are undiagnosed due to infrequent self-
reporting of functional impairment/ decline
• Such milder HAND needs to be detected as 
it may precede to further neurodegeneration 
that can potentially be prevented by ART
• In pre-ART patients with CD4+ counts >350 
cells/µl, screening should be performed in 
wellness clinics approximately annually; 
patients with clear neurocognitive disorder 
should be referred for confirmation and 
initiation of ART
• At ART initiation, patients with cognitive 
problems may require additional treatment 
support; a baseline assessment allows track-
ing over time of progress/recovery
• Once receiving ART, patients with HAND 
may require additional adherence support
• HAND may progress or fail to recover 
despite ART
• Should be offered as part of adherence 
support or may be offered annually, or where 
resources are limited, reserved for those 
with clinical problems (treatment failure, 
poor ad her ence, on-going depression, self-
reported functional impair ment).
6.2  Approaches to screening 
for HAND
• There is no globally accepted screening 
policy or practice
• An ultra-brief symptoms-based tool[23] may 
detect more severe cases (see Table 3)
• Other tools proposed for use include: 
• International HIV Dementia Scale 
(IHDS) (validated in SA) (http://
www.europeanaidsclinicalsociety.org/
Guidelines/G2_pC.htm)
• Montreal Cognitive Assessment (MOCA) 
(http://www.mocatest.org)
• the HIV-Dementia scale (http://www.
turkpsikiyatri.org/arsiv/category/3-eng.
html?...93:hiv-dementia)
• Cognitive Assessment Tool – Rapid Ver-
sion (awaiting validation) (http://www.
hivmentalhealth.co.za/.../Cognitive-
Assessment-Tool-paper-version2.pdf)
• A positive screen does not equate to a diag-
nosis of HAND; three further steps are 
required for clinical confirmation (Table 4).
6.3  Management (Fig. 5)
• Pre-ART, with confirmed HAND: comm-
ence ART, irrespective of CD4+ count; engage 
family/partner for treatment support; and 
diagnose and treat confounding conditions
• Receiving ART, with HAND: usually mild/
Box 6. MND v. HIV-D
Incidence
• HIV-D in untreated HIV: 35/1 000 
person years
• HIV-D in patients receiving ART: 
3/1 000 person years
Prevalence (SA)
• MND, pre-ART: 42.4%
• MND, while receiving ART: 25.4%[22] 
Impact
• HIV-associated neuro-invasion results 
in a spectrum of neurological effects, 
ranging from subclinical to advanced 
dementia
• Milder (or subclinical) HAND, which 
often persists during ART, has significant 
effects on functional outcomes, e.g. poor 
adherence, unemployment
• Increasing HIV testing uptake, earlier 
access to ART and adherence support 
will positively impact rates of HAND in 
HIV-positive populations
Fig. 4. Recognising (a) primary and (b) secondary SMDs. (BMD = bipolar mood disorder; SMD = severe mental 
disorder; HAD = HIV-associated dementia; AMC = another medical condition; HAND = HIV-associated 
neurocognitive disorder; ART = antiretroviral therapy; MDD = major depressive disorder; SGA = second-
generation antipsychotic; FGA = first-generation antipsychotic.)
Primary psychiatric illness
Schizophrenia BMD type 1 MDD with psychosis
Exclude GMC and substance abuse
Refer for further psychiatric management
Two or more symptoms
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moderate disease but, with ageing popula-
tions, more advanced disease may develop
• Routine VL monitoring with enhanced 
support, if adherence is poor
• Screen and treat comorbidities including 
age-related dementia
• Adjusting the ARV regimen to en hance CNS 
penetration (CPE) is not recommended, as 
the evidence in this regard is conflicting
• Measure the cerebrospinal fluid VL if 
viral compartmentalisation is suspected 
(low CD4+ nadir, severe impairment, 
confusional symptoms, increased tone 
and psychomotor slowing despite viral 
suppression in plasma)
• Augmentation strategies, including meman-
tine, are not recommended due to the lack of 
robust supporting evidence and cost
• Sodium valproate or lithium may be used if 
there is neuropsychiatric comorbidity.
7.  Grief and loss in 
the context of HIV 
Grief is a normal, non-pathological response 
to any type of loss, not just death. The grief 
response is highly individualised as it is influ-
enced by individual, cultural, religious, familial, 
community and societal factors. Grief arising 
from a loss related to HIV may be particularly 
complicated; complicated grief is defined as a 
prolonged period of intensified grief symptoms 
that disrupt daily functioning.[24] 
7.1 Screening
• Screen for common symptoms of grief:
• emotional: enduring sadness, shock, 
anger, anxiety, loneliness, yearning, guilt, 
Table 3. Simioni Neurocognitive Symptom Questions[23]
Ask the patient the following questions. Each answer should include one of ‘never’, ‘hardly ever’, or ‘yes, definitely’. Any one ‘yes, 
definitely’ answer equals a positive screen.
Question Never Hardly ever Yes, definitely
Do you experience frequent memory loss (e.g. do you forget the occurrence of special events, even 
more recent ones, appointments, etc.)? ☐ ☐ ☐
Do you feel that you are slower when reasoning, planning activities or solving problems? ☐ ☐ ☐
Do you have difficulties paying attention (e.g. to a conversation, a book or a movie)? ☐ ☐ ☐




1. Is neuropsychological impairment present? (use symptom questions and at least one brief 
objective measure e.g. IHDS, MMSE, HDS, MoCA) ☐ ☐ ☐
2. To what extent are confounding illnesses contributing to the neurocognitive disorder? (depression, 
alcohol abuse, head injury, epilepsy, nutritional deficiency, CNS OI and neurosyphilis) ☐ ☐ ☐
3. Is functional impairment present? (measure basic daily activities including pill-taking and 
complex tasks, e.g. cleaning, cooking, shopping, money management, work tasks or driving) ☐ ☐ ☐
IHDS  = International HIV Dementia Scale; MMSE = mini mental state examination; HDS = HIV dementia scale; MoCA = Montreal Cognitive Assessment; CNS = central nervous system;  
OI = opportunistic infection; HIV-D = HIV-dementia; MND = mild neurocognitive disorder; NP = neuropsychological; HCWs = healthcare workers; CT = computed tomography.
Clinicians then need to confirm whether HIV-D or MND is present:
• HIV-D: severe NP impairment + at least mild - moderate functional impairment +/- mild - moderate contribution from confounders. 
• MND: either Severe NP impairment + no reported functional impairment, or mild - moderate NP impairment + at least mild - moderate functional impairment.
* Notes:  Step 1: Clinicians may perform more advanced neuropsychological testing or combine bedside tests. Primary HCWs may refer patients for such detailed assessment.
Step 2: If clinical examination reveals no focal abnormality or comorbid medical conditions, lumbar puncture, CT scanning and blood tests rarely add diagnostic information. If delirium, 
confusion or psychiatric/behavioural symptoms are present, these further investigations are mandatory. Actively manage underlying confounding conditions.
Step 3: The extent of functional impairment is often under-rated – seek objective measures including third-party reports and clinical assessment of simple tasks where possible.
Fig. 5. Screening and management of HANDs. (CPE = CNS penetration effectiveness.)
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ART preparation
ART experience
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fear, withdrawal, feeling worthless, apathy, 
irritability, appetite disturbances
• physical: fatigue, tightness in the chest, 
shortness of breath, lack of energy, 
numbness, nausea, body aches, panic 
attacks, insomnia
• psychological/cognitive: disbelief, con fu-
sion, sense of presence, lack of concen-
tration, auditory hallucinations (hearing the 
voice of the deceased), intrusive thoughts, 
anxiety about death, mental fatigue
• spiritual distress: questioning faith or the 
meaning of being a survivor
• Explore the nature and relationship of the 
loss/death and its impact
• Assess if the grief reaction is appropriate for 
the setting/cultural context
• Assess the griever’s coping style, support 
network, and previous experiences of loss 
or death
• Assess for barriers to effective grieving, e.g. 
a lack of support, multiple losses, mental 
health issues, a complex relationship with 
the deceased, the manner of death, etc.
• The screening of children and adolescents 
needs to be age-appropriate and cognisant 
of the multiple subsequent losses that can 
arise following parental/caregiver death, 
e.g. separation from siblings, new school/
friends, new home, etc.
• Clinicians may have trouble distinguishing 
grief and bereavement from depression (see 
Table 5; refer to Fig. 6 for the management 
of acute grief and bereavement)
8.  Burnout and 
vicarious trauma
HCWs may also experience emotional 
and psychological effects from exposure to 
cumulative challenges within the health sector. 
While taking care of oneself is a prerequisite to 
taking good care of others, stigma persists for 
HCWs acknowledging burnout and vicarious 
trauma. Table 6 highlights key symptoms 
indicative of burnout and vicarious trauma.[29]
8.1 Burnout
• Prolonged involvement in emotionally 
demanding situations results in gradual 
progression towards: (i) emotional ex haus-
tion; (ii) depersonalisation; and (iii) a re -
duc ed personal accomplishment and 
commit ment to one’s profession
• Risk factors include: a high patient load; 
difficult patient circumstances; HCW em -
pathy, own experiences, age, training, lack 
of control and failure to care for oneself; 
and organisational characteristics (a lack of 
support/recognition/fairness, low salaries)
• Failure to recognise burnout may lead to 
depression or chronic fatigue[27]
• Burnout can be assessed officially using 
the Maslach Burnout Inventory (MBI) 
(http://www.mindgarden.com/products/
mbi.htm) or the Oldenburg Burnout 
Inventory (OBI) (http://www.bma.org.uk/
burnoutquestionnaire).
Table 5. Differentiating grief/bereavement from depression[25]
Grief/bereavement Depression
Expected, culturally accepted response to loss
Guilt is focused on an aspect of loss
Moments of pleasure/happiness
Preoccupation with deceased
Not demoralising or humiliating
Overt expression of anger
Diminishes in intensity over time
Suicidal gestures are rare
Responsive to support
Elicits sympathy, concern and desire to embrace
Usually functions
Only diagnose depression if the griever experiences depressive 
symptoms persisting for ≥2 months
Guilt is preoccupied with a negative self-image
Feelings of emptiness and despair are constant
Preoccupation with self
Demoralising and humiliating
Anger not as pronounced
Consistent sense of depletion
Suicidal gestures are not unusual 
Unresponsive to support
Elicits irritation, frustration and a desire to avoid from others
Inability to function at work, home and/or school 
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8.2 Vicarious trauma
Repeated exposure to patients’ traumatic 
stories may result in intrusive imagery, 
avoidance/hyperarousal, experiencing symp-
toms similar to the patients’ trauma response 
(confusion, tearfulness, iso lation, anger, irrita-
bility, powerlessness, hope less ness), increased 
vulnerability and/or sur vivor guilt.[28]
8.3 Management
• The individual clinician can manage 
burnout by following the 3 ‘r’ approach:[30]
• recognise: watch carefully for signs of 
burnout
• reverse: undo damage by using stress-
management techniques and employing 
support from fellow HCW and family
• resilience: build resilience to stress by 
looking after your physical and mental 
health
• When recovering from burnout: slow down; 
re-evaluate goals and priorities; and get 
support.
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Table 6. Symptoms of HCW burnout and vicarious trauma
Burnout Vicarious trauma
Individual level
• Overextended emotionally and physically by his/her work environment
• Responds to colleagues/patients in an impersonal way
• Feels no sense of accomplishment in anything that he/she does
• Physical exhaustion: fatigue; insomnia; weight fluctuations
• Emotional exhaustion: feeling responsible; psychosomatic symptoms
• Psychological exhaustion: compassion fatigue
• Absenteeism
Individual level
• Feeling overwhelmed/helpless when hearing patients’ trauma stories 
• Feeling ineffective, unskilled and/or powerless
• Intrusive imagery of the trauma stories that they hear about
• Hyperarousal
• Avoidance of places, people or work
• Feeling angry and irritable
• Disconnect from other staff members
Organisational level
• Absenteeism and high staff turnover
• Disengaged from colleagues/patients
• Increased team conflict
• Insufficient staff training/technical ability and lack of resources
Organisational level
• Impact of trauma stories on staff not acknowledged/recognised
• Disengaged from colleagues/patients
• Increased team conflict/poor teamwork
• Insufficient training of staff to manage emotional impact of trauma
